5-aza-2′-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells

Annals of Oncology

Volumn 5, Issue 3, 1994, Pages 269-276

  Caraglia, M ^a   Pinto, A ^b   Correale, P ^a   Zagonel, V ^b   Genua, G ^a   Leardi, A ^a   Pepe, S ^a   Bianco, A R ^a   Tagliaferri, P ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

5 aza 2 deoxycytidine; Epidermal growth factor receptor; Epithelial cancer cells; Monoclonal antibody; Targeting

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR;

ARTICLE; CARCINOMA; CELL GROWTH; EPITHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AZACITIDINE; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; ENDOCYTOSIS; HUMAN; KB CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0028269939     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a058806     Document Type: Article

References (41)

1. M.S. Miller Biological Approaches to Cancer Treatment M.S. Mitchell Health Profession Division 1993 McGraw-Hill, Inc New York, NY 10 13
2. S. Waxman The importance of the induction of gene expression and differentiation by cytotoxic chemotherapy Cancer Invest 6 1988 747 753
3. S.M. Taylor P.A. Jones Changes in phenotypic expression in embryonic and adult cells treated with 5-azacytidine J Cell Physiol 111 1982 187 194
4. G.E. Francis J.M. Cunningham Growth and differentiation control H.M. Pinedo D.L. Longo B.A. Chabner Cancer Chemotherapy and Biological Response Modifiers, Annual 12 1991 Elsevier Publishers BV Amsterdam 251 290
5. R.L. Momparler Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine Pharmacol Ther 30 1985 287 299
6. P.A. Jones S.M. Taylor Cellular differentiation, cytidine analogues, and DNA methylation Cell 20 1980 85 93
7. P.A. Jones Altering gene expression with 5-azacytidine Cell 40 1985 485 486
8. S.F. Konieczny C.P. Emerson Jr. 5-Azacytidine induction of stable mesodermal stem cell lineages from T10 1/2 cells: Evidence for regulatory genes controlling determination Cell 39 1984 791 800
9. S.M. Taylor 5-Aza-2′-deoxycytidine, cell differentiation and DNA methylation Leukemia 1 1993 3 8
10. A. Pinto V. Attadia A. Fusco 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemia Blood 64 1984 922 929
11. C. Sung R. Shockley Ty P.F. Morrison Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors Cancer Res 52 1992 377 384
12. K. Fujimori D.R. Fisher J.N. Winstein Integrated microscopicmacroscopic pharmacology of monoclonal antibody radioconjugates: The radiation dose distribution Cancer Res 51 1991 4821 4827
13. M. Toi T. Nakamura H. Mukaida Relationship between epidermal growth factor status and various prognostic factors in human breast cancer Cancer 65 1990 1980 1984
14. W.J. Gullick J.J. Marsden N. Whittle Expression of epidermal growth factor receptors on human cervical, ovarian and vulval carcinomas Cancer Res 46 1986 285 292
15. T.A. Liebermann N. Razon A.D. Bartal Expression of epidermal growth factor receptors in human brain tumors Cancer Res 44 1984 753 760
16. J. Mendelsohn Growth factor receptors as targets for antitumor therapy with monoclonal antibodies H. Waldman Monoclonal Antibody Therapy. Prog Allergy 1988 Karger Basel 121 146 45
17. G.H. Sato J.D. Sato Growth factor receptor monoclonal antibodies and cancer immunotherapy J Natl Cancer Inst 81 1989 1600 1601
18. H. Bender H. Takahashi K. Adachi Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor Cancer Res 52 1992 121 126
19. C.R. Dvigi S. Welt M. Kris Phase I and imaging trial of indium 111–labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma J Natl Cancer Inst 83 1991 97 104
20. I. Pastan D.J. Fitzgerald Recombinant toxins for cancer treatment Science 254 1991 1173 1178
21. A. Budillon P. Tagliaferri M. Caraglia Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells Cancer Res 51 1991 1294 1299
22. V.S. Byers I.Z.A. Pawluczyk D.S. Hooi Endocytosis of immunotoxin-791T/3-RTA by tumor cells in relation to its cytotoxic action Cancer Res 51 1991 1190 1195
23. M.P. Stoppelli C. Tacchetti M.V. Cubellis Autocrine saturation of pro-urokinase receptor on human A431 cells Cell 45 1986 675 684
24. G. Scatchard The attraction of proteins for small molecules and ions Ann NY Acad Sci 51 1949 600 672
25. P.J. Munson D. Rodbard Ligand: A versatile computerized approach for characterization of ligand binding systems Anal Biochem 107 1980 220 239
26. F. Bellot W. Moolenaar R. Kris High affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses J Cell Biol 110 1990 491 502
27. J.W. Greiner P. Horan Hand P. Noguchi Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment Cancer Res 44 1984 3208 3214
28. E. Ruff A. Rizzino Preparation and binding of radioactively labeled porcine transforming growth factor type beta Biochem Biophys Res Commun 138 1986 714 719
29. A. Rizzino P. Kazakoff E. Ruff Regulatory effects of cell density on the binding of transforming growth factor-ß, epidermal growth factor, platelet-derived growth factor and fibroblast growth factor Cancer Res 48 1988 4266 4271
30. L. Beguinot R.M. Lall M.C. Willingham I. Pastan Down regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes Proc Nad Acad Sci USA 81 1984 2384 2388
31. A. Pinto V. Zagonel 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends Leukemia 7 1993 51 60
32. D. Santi C.E. Garrett P.J. Barr On the mechanism of inhibtion of DNA-cytosine methyltransferase by cytidine analogs Cell 83 1983 9 10
33. H. Cedar DNA methylation and gene activity Cell 53 1983 3 4
34. S. Davidson P. Crowther J. Radley D. Woodcock Cytotoxicity 5-aza-2’-deoxycytidine in a mammalian cell system Eur J Cancer 28 1992 362 368
35. R.L. Momparler M. Gyger G.E. Rivard Clinical trial on 5-aza-2’-deoxycytidine in patients with acute leukemia Pharmacol Ther 30 1985 277 286
36. R. Willemze D.J. Richel M.W. Arentsen-Honders L.P. Colly 5-Aza-2′-deoxycytidine (DAC) in patients with resistant and relapsed acute leukaemia Br J Cancer 64 1991 144 148
37. V. Attadia Effects of 5-aza-2’-deoxycytidine on differentiation and oncogene expression in the human monoblastic cell line U937 Leukemia 7 1993 9 16
38. B.J. Braakhuis G.A. Van Dongen M. Van Walsum Preclinical antitumor activity of 5-Aza-2′-deoxycytidine against human dead and neck cancer xenografts Invest New Drugs 6 1988 299 304
39. A. Goldenberg H. Masui C. Dvigi EGF overexpression and localization of nude mouse xenografts using an indium-111–labeled anti-EGF-receptor monoclonal antibody J Natl Cancer Inst 81 1989 1616 1619
40. V. Zagonel V. Lo Re G. Marotta 5-Aza-2′-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndrome Leukemia 7 1993 30 35
41. L. Debusscher J.P. Marie P. Dodion Phase I–II trial of 5-aza-2′-deoxycytidine in adult patients with acute leukemia R.L. Momparler De Vos 5-Aza-2′-deoxycytidine: Preclinial and Clinical studies. Haarlem 1990 PHC Publications The Netherlands 131 142